Ozempic vs Mounjaro vs Wegovy: What's the Difference?

When your doctor mentions GLP-1 therapy, you might encounter a confusing array of brand names. Ozempic, Wegovy, Mounjaro, Zepbound — what's the difference? This guide cuts through the confusion so you can have an informed conversation with your healthcare provider.

The Quick Overview

• Ozempic (semaglutide): FDA-approved for type 2 diabetes; widely used off-label for weight loss
• Wegovy (semaglutide): Same drug as Ozempic but at higher doses, FDA-approved specifically for weight loss
• Mounjaro (tirzepatide): FDA-approved for type 2 diabetes; dual GLP-1/GIP agonist
• Zepbound (tirzepatide): Same as Mounjaro, FDA-approved specifically for weight loss

How They Work Differently

Semaglutide (Ozempic / Wegovy)

Semaglutide is a GLP-1 receptor agonist — it mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve blood sugar control. It's injected once weekly and has a proven track record spanning nearly a decade of clinical use.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is often called a "twincretin" because it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action appears to produce greater weight loss than GLP-1 alone in clinical trials.

In the SURMOUNT-1 trial, tirzepatide 15mg produced an average weight loss of 22.5% of body weight over 72 weeks — among the highest ever recorded for a non-surgical obesity treatment.

Weight Loss Comparison

Clinical trial data (not head-to-head, so comparisons should be made cautiously):

• Ozempic 1mg (SUSTAIN trials): ~4-6 kg average weight loss in diabetes patients
• Wegovy 2.4mg (STEP trials): ~15% body weight loss over 68 weeks
• Mounjaro/Zepbound 15mg (SURMOUNT trials): ~22% body weight loss over 72 weeks

Side Effect Profiles

All GLP-1 medications share similar side effect profiles, dominated by gastrointestinal symptoms:

• Nausea (most common, especially at dose increases)
• Vomiting
• Diarrhea or constipation
• Stomach pain
• Decreased appetite (also the intended effect)

Tirzepatide's dual mechanism may cause slightly different GI tolerability for some patients — some find it better tolerated, others worse. Individual responses vary significantly.

Cost and Insurance Coverage

Cost is often the deciding factor in the real world:

• Ozempic list price: ~$935/month; often covered for T2D diagnosis
• Wegovy list price: ~$1,350/month; coverage for obesity varies widely
• Mounjaro list price: ~$1,069/month; often covered for T2D diagnosis
• Zepbound list price: ~$1,059/month; newer, coverage still expanding

Which One Is Right for You?

Only your healthcare provider can make this determination. Factors they'll consider include your primary diagnosis (diabetes vs. obesity), insurance coverage, prior medication history, and your specific side effect tolerance. Don't be afraid to ask about all options.